Intrexon Corp. signed a cooperative research and development agreement with NCI for the development of adoptive T cell therapies utilizing the RheoSwitch Therapeutic System platform for the treatment of solid tumor malignancies.
MD Anderson Preempts AAUP's Report By Releasing the Draft to the Press—With a ForewordBy Matthew Bin Han Ong
Mark Green, former director of Hollings Cancer Center at the Medical University of South Carolina and the University of California, San Diego, Moores Cancer Center, died Feb. 23, at the age of 70.
The National Cancer Institute Harold Varmus will leave on March 31 is leaner, cleaner, and more focused than it was on July 12, 2010, the day he became its 14th director.
NCI Director Harold Varmus announced that he will be stepping down at the end of this month.
Meir Wetzler, 60, chief of the Leukemia Section at the Roswell Park Cancer Institute, died Feb. 23, nearly two weeks after a skiing accident in Denver, Colo.
Faculty Urges UT System to Help Fix MD Anderson's Woes
Rising 19,341 feet above sea level, Mt. Kilimanjaro is the highest mountain in Africa and the tallest freestanding mountain in the world. It is a dormant but non-extinct volcano which last erupted some 150,000 years ago.
Last week, it was reported in both The Cancer Letter and the Houston Chronicle that The University of Texas MD Anderson Cancer Center had closed a deal to sublicense intellectual property to two pharmaceutical firms, Intrexon and Ziopharm Oncology. There is nothing terribly unusual about that.
On Jan. 9, 2015, The Cancer Letter reported that Duke University received information in early 2008 that called into question the validity of the methodology and results published by the Anil Potti research group. Potti, along with his mentor and co-author Joseph Nevins, had galvanized the world of cancer research in 2006 and 2007 with their reports of successful gene expression tests for directing cancer therapy, the “holy grail” of cancer research. The 2008 information came in the form of a letter from a third-year medical student, Brad Perez, who was working in Potti's lab. The letter, which does not seem to have been given any credence at the time, described with precision the problems that eventually resulted in the termination of clinical trials and the subsequent retractions, beginning in 2011, of at least ten (and counting) papers from major scientific journals.
